Project description DEENESFRITPL Rehabilitation at home Stroke may leave patients with motor impairment and difficulty in undertaking everyday tasks such as walking or eating. Functional electrical stimulation (FES) is a treatment method that applies electrical impulses to nerves or muscles as a rehabilitation strategy. The EU-funded WalkHome project has developed a neuroprosthetic device that utilises FES to treat foot drop, the difficulty of lifting the front part of the foot. The main advantage is that it allows tailored rehabilitation treatment at the comfort of one’s home and at significantly lower cost. Moreover, it will improve the independence and quality of life of stroke patients. Show the project objective Hide the project objective Objective The ContextStroke has huge human and economic cost. 1 million people suffer strokes in Europe every year, with an average life expectancy after stroke of 8 years. Roughly 20% of stroke survivors suffer from drop foot, with 45 billion euros spent on rehabilitating stroke patients in Europe every year.The opportunity: FES offers the tantalising prospect of retraining voluntary motor functions such as walking. However:- FES rehabilitation must be carried out in a hospital with the support of trained healthcare professionals;- Transporting patients and supervising treatment is expensive;- Patient’s treatment plan is sub-optimal;- Per patient rehabilitation costs reach 32,000 euros Our solution: Fesia WalkHome is a FES rehabilitation device for drop foot patients which can be administered by the patient in their own home. This not only reduces costs by 43% but also means patients can have an optimal treatment plan, improving their speed of recovery. The use of Fesia Walk at home will give autonomy, independence and improve the quality of life for chronic patients. It will also mean a substantial reduction of waiting lists, health costs, number of physician office visits, and carer support.The Project:WalkHome represents a disruptive change of paradigm for the FES rehabilitation standard of care. The aim of the phase 1 project is to improve our understanding of the EU market for FES rehabilitation, identifying regional market variations in terms of key decision makers, appropriate business models, pricing structure and identifying which are the most attractive markets for us to use as a beachhead. We will also analyse what key improvements need to be made to the existing technology to create the new FES home care rehabilitation market.The Market:Currently, there is no FES rehabilitation technology that is offered outside of a clinical setting. We estimate that this new home FES rehabilitation market could be worth up to 40 billion euros in Europe alone. Fields of science medical and health sciencesclinical medicinephysiotherapysocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesbasic medicinepathologymedical and health sciencesbasic medicineneurologystrokemedical and health sciencesclinical medicineorthopaedics Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator FESIA TECHNOLOGY SL Net EU contribution € 50 000,00 Address PASEO MIKELETEGI 58 PARQUE CIENTIFICO Y TECNOLOGICO DE GIPUZKOA 20009 DONOSTIA SAN SEBASTIAN Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noreste País Vasco Gipuzkoa Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
